PW Medtech (01358) has released its interim results for the six months ended June 30, 2026, showing a significant decline in profitability. The group recorded revenue of RMB 394 million, representing a year-on-year decrease of 4.9%, while profit attributable to owners of the company amounted to RMB 14.692 million, down sharply by 77.74% compared to the same period last year.

Earnings per share stood at RMB 1.01 cents, with an interim dividend of HK 1.1 cents per share declared. The company attributed the revenue decline primarily to reduced sales in its infusion set business, which was partially offset by growth in its blood purification segment and regenerative medical biomaterials business.